Conference Coverage

Antimalarials prove protective against long-term lupus damage

Publish date: November 18, 2013

 

AT THE ACR ANNUAL MEETING

Power calculations based upon the SLICC Inception Cohort Study suggest such trials could be relatively modest in size, he added.

SLICC receives financial support from GlaxoSmithKline, Bristol-Myers Squibb, and Human Genome Sciences. Dr. Bruce reported receiving research funding from GlaxoSmithKline, Bristol-Myers Squibb, Roche, and UCB.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Biologic therapy doesn’t preclude vaccinating psoriasis patients
Psoriasis Collection
Apremilast promising for Behçet’s syndrome
Psoriasis Collection
Treatment adherence poor among Medicaid beneficiaries with lupus
Psoriasis Collection
Systemic sclerosis brings sharply increased MI risk
Psoriasis Collection
Treat-to-target approach for psoriatic arthritis found beneficial
Psoriasis Collection
Novel predictor of poor outcomes in lupus pregnancies
Psoriasis Collection
Abatacept may reduce maintenance immunosuppression need in lupus nephritis
Psoriasis Collection
Cyclophosphamide and rituximab combo reduced severe lupus flares
Psoriasis Collection
Apremilast’s positive study results made it the talk of ACR 2013
Psoriasis Collection
Depression accounts for psoriatics’ increased MI risk
Psoriasis Collection